Case reports of postmarketing adverse event experiences with olanzapine intramuscular treatment in patients with agitation

Journal of Clinical Psychiatry

Volumn 71, Issue 4, 2010, Pages 433-441

  Marder, Stephen R ^a   Sorsaburu, Sebastian ^c   Dunayevich, Eduardo ^b   Karagianis, Jamie L ^d   Dawe, Ian C ^e   Falk, Deborah M ^c   Dellva, Mary Anne ^c   Carlson, Janice L ^c   Cavazzoni, Patrizia A ^c   Baker, Robert W ^c  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b Orexigen Therapeutics   (United States)

^c ELI LILLY AND COMPANY   (United States)

^d Eli Lilly and Company   (Canada)

^e ST MICHAEL'S HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ACICLOVIR; ALA CORT; ALPRAZOLAM; AMISULPRIDE; AMOXICILLIN; BENZATROPINE MESILATE; BENZODIAZEPINE DERIVATIVE; BIPERIDEN; BISOPROLOL FUMARATE; CARBAMAZEPINE; CEFTRIAXONE; CEFUROXIME; CEFUROXIME AXETIL; CHLORPROMAZINE; CHLORPROTHIXENE; CLONAZEPAM; CLORAZEPATE; CLORAZEPATE DIPOTASSIUM; CLOZAPINE; CYCLOBARBITAL; DIAZEPAM; DICLOFENAC; DOXAZOSIN; ESZOPICLONE; FENTANYL; FERROUS FUMARATE; FLUPENTIXOL DECANOATE; FUROSEMIDE; HALOPERIDOL; HALOPERIDOL DECANOATE; HI COR; INSULIN ASPART; INSULIN DETEMIR; LAMOTRIGINE; LEVO T; LEVOMEPROMAZINE; LEVOTHYROXINE SODIUM; LITHIUM CARBONATE; LORAZEPAM; METHYLPREDNISOLONE; METHYLPREDNISOLONE ACETATE; MIRTAZAPINE; NEUROLEPTIC AGENT; NIKETHAMIDE; OLANZAPINE; OMEPRAZOLE; ONSOLIS; PHENYTEK; PHENYTOIN; PROMAZINE; PROMETHACON; PROMETHAZINE; PROMETHEGAN; PROPRANOLOL; QUETIAPINE; RISPERIDONE; RYZOLT; STAVZOR; TRAMADOL; TRIHEXYPHENIDYL; UNCLASSIFIED DRUG; UNINDEXED DRUG; VALPROIC ACID; ZIPSOR; ZOTEPINE; ZUCLOPENTHIXOL; ZUCLOPENTHIXOL DECANOATE;

ADOLESCENT; ADULT; AGED; AGITATION; ARTICLE; BIPOLAR DISORDER; CENTRAL NERVOUS SYSTEM DISEASE; COMORBIDITY; CREATINE KINASE BLOOD LEVEL; DEMENTIA; DEPRESSION; DRUG SAFETY; FALLING; FATALITY; FEMALE; FEVER; HEART ARREST; HEART DISEASE; HUMAN; MAJOR CLINICAL STUDY; MALE; MENTAL DISEASE; NEUROLEPTIC MALIGNANT SYNDROME; POSTMARKETING SURVEILLANCE; PRIORITY JOURNAL; PSYCHOSIS; RESPIRATORY TRACT DISEASE; SCHIZOPHRENIA; SIDE EFFECT; SOMNOLENCE; VASCULAR DISEASE;

ADOLESCENT; ADULT; ADVERSE DRUG REACTION REPORTING SYSTEMS; AGED; AGED, 80 AND OVER; ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; BIPOLAR DISORDER; CHILD; DATABASES AS TOPIC; FATAL OUTCOME; FEMALE; HUMANS; INJECTIONS, INTRAMUSCULAR; MALE; MIDDLE AGED; PSYCHOMOTOR AGITATION; RISK FACTORS; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY; TREATMENT OUTCOME;

EID: 77951039041     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: 10.4088/JCP.08m04411gry     Document Type: Article

References (19)

1. Hassall C, Prior P, Cross KW. A preliminary study of excess mortality using a psychiatric case register. J Epidemiol Community Health. 1988; 42(3):286-289.
2. Waddington JL, Youssef HA, Kinsella A. Mortality in schizophrenia: antipsychotic polypharmacy and absence of adjunctive anticholinergics over the course of a 10-year prospective study. Br J Psychiatry. 1998;173:325-329. (Pubitemid 28454819)
3. Reay DT, Howard JD, Fligner CL, et al. Effects of positional restraint on oxygen saturation and heart rate following exercise. Am J Forensic Med Pathol. 1988;9(1):16-18.
4. Ross DL. Factors associated with excited delirium deaths in police custody. Mod Pathol. 1998;11(11):1127-1137.
5. Harvey MA. Managing agitation in critically ill patients. Am J Crit Care. 1996;5(1):7-16. (Pubitemid 126479570)
6. Battaglia J. Pharmacological management of acute agitation. Drugs. 2005;65(9):1207-1222.
7. Stern TA. Continuous infusion of haloperidol in agitated, critically ill patients. Crit Care Med. 1994;22(3):378-379. (Pubitemid 24085285)
8. Breier A, Meehan K, Birkett M, et al. A double-blind, placebo-controlled dose-response comparison of intramuscular olanzapine and haloperidol in the treatment of acute agitation in schizophrenia. Arch Gen Psychiatry. 2002;59(5):441-448. (Pubitemid 34477680)
9. Meehan K, Zhang F, David S, et al. A double-blind, randomized comparison of the efficacy and safety of intramuscular injections of olanzapine, lorazepam, or placebo in treating acutely agitated patients diagnosed with bipolar mania. J Clin Psychopharmacol. 2001;21(4):389-397. (Pubitemid 32673028)
10. Wright P, Lindborg SR, Birkett M, et al. Intramuscular olanzapine and intramuscular haloperidol in acute schizophrenia: antipsychotic efficacy and extrapyramidal safety during the first 24 hours of treatment. Can J Psychiatry. 2003;48(11):716-721. (Pubitemid 38197030)
11. Garza-Trevino ES, Hollister LE, Overall JE, et al. Efficacy of combinations of intramuscular antipsychotics and sedative-hypnotics for control of psychotic agitation. Am J Psychiatry. 1989;146(12):1598-1601.
12. Meehan KM, Wang H, David SR, et al. Comparison of rapidly acting intramuscular olanzapine, lorazepam, and placebo: a double-blind, randomized study in acutely agitated patients with dementia. Neuropsychopharmacology. 2002;26(4):494-504. (Pubitemid 34260999)
13. Cooper JW. Adverse drug reaction-related hospitalizations of nursing facility patients: a 4-year study. South Med J. 1999;92(5):485-490.
14. Kryzhanovskaya LA, Jeste DV, Young CA, et al. A review of treatment-emergent adverse events during olanzapine clinical trials in elderly patients with dementia. J Clin Psychiatry. 2006;67(6):933-945. (Pubitemid 44049092)
15. Davidson S, Judd F, Jolley D, et al. Cardiovascular risk factors for people with mental illness. Aust N Z J Psychiatry. 2001;35(2):196-202. (Pubitemid 32377538)
16. Brown S, Birtwistle J, Roe L, et al. The unhealthy lifestyle of people with schizophrenia. Psychol Med. 1999;29(3):697-701.
17. Lee TW, Tsai SJ, Hwang JP. Severe cardiovascular side effects of olanzapine in an elderly patient: case report. Int J Psychiatry Med. 2003;33(4):399-401.
18. Markowitz JS, DeVane CL, Boulton DW, et al. Hypotension and bradycardia in a healthy volunteer following a single 5 mg dose of olanzapine. J Clin Pharmacol. 2002;42(1):104-106.
19. Fava M. Psychopharmacologic treatment of pathologic aggression. Psychiatr Clin North Am.1997;20(2):427-451.